Side-by-side · Research reference

HGH Fragment 176-191vsVilon

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED28/59 cited

BAnimal-StrongHUMAN-REVIEWED13/49 cited

HGH Fragment 176-191

GH Fragment · Pre-Clinical

50%Weight gain reductionNg 2000

~26 minHalf-life (est.)

No IGF-1 ↑GH axis impact

SQ · IP (animal) · Oral (tested)

Vilon

Khavinson Bioregulator · Dipeptide

2 AADipeptide

T-helperStimulatesLinkova 2011

MouseModel basisKhavinson 2002

Literature lacks standardised clinical route

01Mechanism of Action

Parameter

HGH Fragment 176-191

Vilon

Primary target

Beta-3 adrenergic receptors on adipocytesHeffernan 2001

Immune cell differentiation pathways, chromatin modification

Pathway

Fragment → β3-AR upregulation → Enhanced lipolytic sensitivityHeffernan 2001

Vilon → Thymocyte sphingomyelinase activation → T-helper & cytotoxic T-cell differentiation; epigenetic suppression of aging markers (CCL11, HMGB1)

Downstream effect

Increased lipolysis and beta-3 AR mRNA expression without IGF-1 axis activation

Enhanced T-cell differentiation (CD4+, CD8+, B-cells), thymocyte proliferation, modulated IL-1β comitogenic activity, proposed chromatin decondensation in aged lymphocytesLinkova 2011 Khavinson 2002 Lezhava 2023

Feedback intact?

N/A — does not interact with GH/IGF-1 axis

Unknown — no HPA/HPG axis data

Origin

Synthetic peptide derived from hGH residues 176-191; AOD9604 includes N-terminal tyrosine (177-191)Cox 2015

Synthetic dipeptide derived from Khavinson thymic peptide extraction studies (Thymalin fraction)Morozov 1997

Antibody development

Not reported in available studies

—

02Dosage Protocols

Parameter

HGH Fragment 176-191

Vilon

Animal dose (oral)

500 mcg/kg body weightNg 2000

Obese Zucker rats, 19 days.

—

Animal dose (IP)

Not specified (14-day chronic administration)Heffernan 2001

Obese mice, daily IP injection.

—

Human equivalent dose

Not established — no published human RCTs

—

Frequency

Once daily (animal models)

Unknown — literature does not specify chronic administration protocols

Evidence basis

Animal studies only

Mouse / in vitro only

Duration tested

14–19 daysHeffernan 2001 Ng 2000

—

Detection window

50 pg/mL LOD in urine; stable metabolite extends detectionCox 2015

WADA-banned; anti-doping testing available.

—

Oral bioavailability

Demonstrated efficacy in animal oral administrationNg 2000

Potential for oral therapeutic development.

—

Standard dose

—

No clinical standard — literature lacks human dosing

Russian practice: often combined with other Khavinson peptides; no FDA/EMA trials.

Animal model dose

—

In vitro: 0.01–10 μg/mL culture medium (mouse thymocytes)

Not translatable to human mg/kg without pharmacokinetic data.

Duration

—

Not characterised in humans

Route

—

Likely SQ or oral (Khavinson school uses both); no published ROA validation

Half-life

—

Not published — dipeptides typically <10 min plasma t½

03Metabolic / Fat Loss Evidence

Parameter

HGH Fragment 176-191

Vilon

Primary fat target

Adipose tissue (general) — beta-3 AR mediated lipolysisHeffernan 2001

—

Weight gain reduction

50% reduction vs control (15.8 ± 0.6 g vs 35.6 ± 0.8 g)Ng 2000

Obese Zucker rats, 19 days oral administration.

—

Body fat reduction

Significant decrease in body weight and body fat in obese mice (14 days)Heffernan 2001

—

Lipolytic activity

Increased adipose tissue lipolytic activityNg 2000

Direct measurement in treated animals.

—

Beta-3 AR expression

Upregulated β3-AR mRNA in obese mice to lean-comparable levelsHeffernan 2001

—

Insulin sensitivity

No adverse effect — euglycemic clamp confirmedNg 2000

Contrasts with intact hGH diabetogenic effects.

—

IGF-1 impact

No elevation — fragment does not activate GH/IGF-1 axis

—

Beta-3 AR dependency

Effect abolished in β3-AR knockout miceHeffernan 2001

Confirms β3-AR as primary mechanism.

—

Route of administration

Efficacy demonstrated via oral and IP routesNg 2000 Heffernan 2001

—

Human evidence

None published — pre-clinical only

—

04Side Effects & Safety

Parameter

HGH Fragment 176-191

Vilon

Insulin sensitivity

No adverse effects observed in euglycemic clamp (animal)Ng 2000

—

GH/IGF-1 axis

No activation — avoids diabetogenic effects of full GHNg 2000

—

Human safety data

Not available — no published human trials

Absent from PubMed-indexed literature

WADA status

Banned as performance-enhancing drugCox 2015

—

Metabolic profile

Six metabolites identified; CRSVEGSCG most stableCox 2015

Detection window implications for doping control.

—

Theoretical risk

—

Immune hyperactivation in autoimmune-prone individuals (T-cell differentiation enhancement)

Antibody formation

—

Not reported; dipeptides generally low immunogenicity

Animal models

—

No adverse effects noted in mouse thymocyte or pineal lymphoid cultures

Absolute Contraindications

HGH Fragment 176-191

·Competitive athletes (WADA-banned)Cox 2015

Vilon

·Active autoimmune disease (theoretical — no clinical data)

Relative Contraindications

HGH Fragment 176-191

·Absence of human safety data — experimental use only

Vilon

·Pregnancy / lactation (no safety data)
·Acute infection with cytokine storm risk (immune modulation unknown)

05Administration Protocol

Parameter

HGH Fragment 176-191

Vilon

1. Route

Subcutaneous injection primary route in research context. Oral administration demonstrated efficacy in animal models at 500 mcg/kg.

No clinical protocols exist in Western peer-reviewed literature. Russian gerontological practice may use 1–10 mg ranges, but dosing is empirical.

2. Frequency

Once daily dosing used in animal studies. Timing not specified; GH-independent mechanism suggests flexibility.

Subcutaneous injection (common for Khavinson peptides) or oral (some bioregulators reportedly active orally due to small size). No validated ROA.

3. Duration

Animal protocols: 14–19 days. Human duration not established — no published trials.

Unknown — no circadian or meal-timing data. Khavinson school often recommends morning administration.

4. Storage

Lyophilized peptide storage per standard peptide protocols. Metabolite stability suggests refrigerated reconstituted solution viable.

Likely lyophilised powder, refrigerated. Reconstitution protocols not published.

5. Detection

Detectable in urine via SPE-LC-MS at 50 pg/mL LOD. Extended detection window via stable metabolite CRSVEGSCG.Cox 2015

—

06Stack Synergy

HGH Fragment 176-191

— no documented stacks

Vilon

+ Epitalon

Moderate

View Epitalon →

Both are Khavinson bioregulators targeting aging pathways. Epitalon (Ala-Glu-Asp-Gly) acts on telomerase and pineal function; Vilon on immune differentiation and chromatin decondensation. Combined in Russian gerontological protocols for multi-system aging intervention. Lezhava et al. (2023) tested both on aged lymphocyte chromatin, showing distinct epigenetic effects. Complementary, not synergistic in strict pharmacological sense.

Vilon: Empirical — no standard
Epitalon: Empirical — often 10 mg cycles
Frequency: Sequential or concurrent (literature ambiguous)
Primary benefit: Multi-system aging modulation (immune + pineal/circadian)

+ Thymalin

Weak

View Thymalin →

Thymalin is the parent polypeptide complex from which Vilon was isolated. Both target immune differentiation, but Thymalin is a complex mixture (multiple peptides), whereas Vilon is a purified dipeptide. Morozov & Khavinson (1997) described Vilon as a synthetic successor designed to replicate Thymalin's immunomodulatory effects with greater specificity. Redundant in practice; no published combination studies.

Vilon: No standard
Thymalin: 10–100 mg IM (polypeptide complex)
Primary benefit: Redundant — both target T-cell differentiation

Morozov 1997 Khavinson 2020